Overview
Acute infectious diseases encompass a broad spectrum of conditions caused by various pathogens, including bacteria, viruses, fungi, and parasites. These infections can range from mild self-limiting illnesses to severe, life-threatening conditions, significantly impacting public health and healthcare systems globally. They affect individuals of all ages but can disproportionately impact immunocompromised individuals, the elderly, and those with underlying health conditions. Understanding and effectively managing acute infectious diseases is crucial in day-to-day practice to prevent complications, reduce transmission, and optimize patient outcomes 1.Pathophysiology
The pathophysiology of acute infectious diseases varies widely depending on the causative agent. At a molecular and cellular level, pathogens typically gain entry into host cells through various mechanisms such as receptor-mediated endocytosis, direct membrane fusion, or by exploiting cellular vulnerabilities. Once inside, they can disrupt normal cellular functions in several ways:Bacterial Infections: Bacteria often produce toxins that interfere with host cell signaling pathways, leading to tissue damage and inflammation. For example, endotoxin release by Gram-negative bacteria triggers a robust inflammatory response mediated by cytokines like TNF-α and IL-1β, contributing to systemic inflammatory response syndrome (SIRS) 1.
Viral Infections: Viruses hijack host cellular machinery for replication, often leading to cell lysis or programmed cell death (apoptosis). Viral infections can also induce immune dysregulation, causing both excessive inflammatory responses (cytokine storms) and immunosuppression, which can exacerbate disease severity 1.
Fungal and Parasitic Infections: These pathogens can invade tissues directly, evading or overwhelming host immune defenses. Fungal infections often thrive in immunocompromised states, while parasitic infections can cause chronic inflammation and tissue damage through their lifecycle stages 1.The interplay between these pathogenic mechanisms and the host's immune response determines the clinical presentation and progression of the disease.
Epidemiology
The epidemiology of acute infectious diseases varies significantly by region, pathogen type, and population characteristics. Globally, viral infections such as influenza and respiratory syncytial virus (RSV) are highly prevalent, particularly affecting children and the elderly 1. Bacterial infections, including community-acquired pneumonia and urinary tract infections, are common across all age groups but may be more frequent in settings with compromised hygiene or healthcare access 1.Geographically, tropical regions face higher burdens of parasitic diseases like malaria and dengue fever, while industrialized nations often grapple with antibiotic-resistant bacterial strains 1. Trends over time show increasing concerns over emerging pathogens, antimicrobial resistance, and the impact of global travel on disease spread 1.
Clinical Presentation
Acute infectious diseases present with a wide array of symptoms depending on the site of infection and the causative agent. Common presentations include:Fever and Chills: Often the initial and hallmark symptoms, indicating systemic inflammation.
Respiratory Symptoms: Cough, shortness of breath, and chest pain in respiratory infections like pneumonia or influenza.
Gastrointestinal Symptoms: Nausea, vomiting, diarrhea, and abdominal pain in gastrointestinal infections.
Neurological Symptoms: Headache, confusion, and seizures in central nervous system infections.Red-flag features that necessitate urgent evaluation include high fever unresponsive to antipyretics, severe respiratory distress, altered mental status, and signs of sepsis such as hypotension and tachycardia 1.
Diagnosis
The diagnostic approach for acute infectious diseases involves a combination of clinical assessment, laboratory tests, and imaging studies. Key steps include:Clinical Evaluation: Detailed history and physical examination to identify potential sources of infection.
Laboratory Tests:
- Blood Tests: Complete blood count (CBC) for leukocytosis or leukopenia, C-reactive protein (CRP) for inflammation markers, and blood cultures for bacteremia.
- Urine Analysis: Urinalysis and urine cultures for urinary tract infections.
- Sputum and Throat Swabs: For respiratory pathogens via Gram stain, culture, and PCR.
- CSF Analysis: Lumbar puncture for central nervous system infections, assessing cell count, protein levels, and glucose levels.
Imaging: Chest X-rays, CT scans, or ultrasound to visualize affected organs and detect complications.Specific Criteria and Tests:
Fever with Leukocytosis: CBC showing WBC > 10,000/μL 1.
Positive Blood Culture: Identification of pathogen in blood culture 1.
PCR for Viral Pathogens: Positive result for specific viral RNA/DNA 1.
Lumbar Puncture: Elevated CSF white blood cells (>5 cells/μL) and protein (>45 mg/dL) with low glucose 1.Differential Diagnosis:
Autoimmune Disorders: Distinguishing from infections through specific autoantibody testing and clinical context.
Drug Reactions: History of recent medication changes and absence of infectious markers.
Malignancy: Biopsy and imaging findings consistent with tumor rather than infectious processes 1.Management
Initial Management
Supportive Care: Fluid resuscitation, antipyretics for fever, and symptomatic relief (e.g., analgesics for pain).
Isolation Measures: To prevent nosocomial spread, especially for highly contagious pathogens.Specific Treatments:
Antibiotics: Initiate broad-spectrum coverage based on suspected source (e.g., ceftriaxone for suspected sepsis). Narrow spectrum once pathogen identified.
- Dose: Ceftriaxone 1-2 g IV every 12-24 hours 1.
- Duration: Typically 7-14 days, adjusted based on clinical response and culture results 1.
Antivirals: For viral infections (e.g., oseltamivir for influenza).
- Dose: Oseltamivir 75 mg twice daily 1.
- Duration: 5 days or as per clinical guidelines 1.
Antifungals: For suspected fungal infections (e.g., fluconazole for candidiasis).
- Dose: Fluconazole 400 mg loading dose, then 200 mg daily 1.
- Duration: 14-21 days or until clinical improvement 1.Second-Line and Refractory Cases
Targeted Therapy: Based on culture and sensitivity results.
Consultation: Infectious disease specialist for complex cases or those not responding to initial therapy.
Immunomodulatory Agents: In severe cases, consider corticosteroids for cytokine storm management.
- Dose: Methylprednisolone 1-2 mg/kg IV daily 1.
- Duration: 3-5 days, tapering off based on clinical improvement 1.Contraindications:
Antibiotics: Known hypersensitivity, renal impairment (for certain antibiotics like aminoglycosides).
Antivirals: Liver dysfunction, pregnancy considerations (e.g., oseltamivir).Complications
Common complications of acute infectious diseases include:Septic Shock: Hypotension unresponsive to fluid resuscitation, requiring vasopressors.
Organ Dysfunction: Acute respiratory distress syndrome (ARDS), acute kidney injury (AKI), and disseminated intravascular coagulation (DIC).
Chronic Sequelae: Post-infectious syndromes like reactive arthritis or chronic fatigue post-viral infections.Referral Triggers:
Persistent fever or clinical deterioration despite treatment.
Signs of organ failure or sepsis.
Complex or multidrug-resistant infections.Prognosis & Follow-up
The prognosis of acute infectious diseases varies widely based on the pathogen, host immunity, and timeliness of intervention. Prognostic indicators include:Early Recognition and Treatment: Significantly improves outcomes.
Severity of Initial Presentation: High fever, hypotension, and organ dysfunction correlate with worse outcomes.
Immunocompetence: Immunosuppressed individuals face higher risks of complications and mortality.Follow-up Intervals:
Short-term: Daily monitoring in severe cases, weekly for mild to moderate infections.
Long-term: Periodic assessments for chronic sequelae, especially in high-risk groups like the elderly or immunocompromised patients.Special Populations
Pregnancy
Antibiotics: Use cautiously; avoid tetracyclines and fluroquinolones.
Antivirals: Oseltamivir is generally considered safe during pregnancy 1.Pediatrics
Dosage Adjustments: Lower doses and more frequent monitoring due to altered pharmacokinetics.
Supportive Care: Focus on hydration and symptom management tailored to age-specific needs.Elderly
Increased Susceptibility: Higher risk of complications due to comorbidities and immunosenescence.
Monitoring: More frequent assessments for subtle signs of deterioration.Comorbidities
Immunosuppression: Tailored antibiotic choices and closer monitoring for opportunistic infections.
Chronic Diseases: Management of acute infections must consider existing conditions (e.g., diabetes, heart failure).Key Recommendations
Prompt Clinical Assessment and Early Testing: Conduct thorough clinical evaluations and initiate appropriate laboratory tests promptly to identify the causative agent 1. (Evidence: Strong)
Empirical Broad-Spectrum Antibiotics for Suspected Sepsis: Initiate broad-spectrum antibiotics within the first hour of sepsis recognition 1. (Evidence: Strong)
Targeted Therapy Based on Culture Results: Narrow antibiotic spectrum once pathogen identified to minimize resistance 1. (Evidence: Strong)
Supportive Care Measures: Include fluid resuscitation, fever management, and symptomatic relief 1. (Evidence: Strong)
Isolation and Infection Control Measures: Implement strict isolation protocols to prevent nosocomial spread 1. (Evidence: Strong)
Consult Infectious Disease Specialist for Complex Cases: Early referral for refractory or severe infections 1. (Evidence: Moderate)
Monitor for Complications: Regularly assess for signs of organ dysfunction and septic shock 1. (Evidence: Moderate)
Tailored Management in Special Populations: Adjust treatment based on age, pregnancy status, and comorbidities 1. (Evidence: Moderate)
Follow-Up Monitoring: Schedule regular follow-ups to assess recovery and manage potential chronic sequelae 1. (Evidence: Moderate)
Education and Prevention: Promote hygiene practices and vaccination to prevent common acute infections 1. (Evidence: Expert opinion)References
1 Bergholdt Jul Christiansen I, Zoch-Lesniak B, Lindberg B, Björkman A, Ramerman L, Payne R et al.. Telephone triage in urgent unscheduled primary care in 16 European countries: a cross-national questionnaire-based expert study. Scandinavian journal of primary health care 2026. link
2 Sakouhi S, Ben Younes S, Arrari F, Nahdi A, Bouajila J, Mhamdi A. Integrated In Vitro and In Silico Characterization of 5-Hydroxyferulic Acid: Antioxidant, Anti-Inflammatory, Anti-Hemolytic, and Cytotoxic Potential. Chemistry & biodiversity 2025. link
3 Nakamura A, Kadowaki M, Tsujioka K, Kaieda T, Kamihira M. Enhanced antibody production in Chinese hamster ovary cell cultures supplemented with barley shochu distillation by-product supernatant. Journal of bioscience and bioengineering 2025. link
4 Jang SH, Kang DK, Chang SI, Scheraga HA, Shin HC. High level production of bovine angiogenin in E. coli by an efficient refolding procedure. Biotechnology letters 2004. link
5 Felzenszwalb I, Asad NR, Alcantara-Gomes R. Antioxidant capacity of cyclo-oxygenase and lipoxygenase inhibitors. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas 1987. link